Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Revenue (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Revenue for 3 consecutive years, with $45000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Revenue fell 80.69% to $45000.0 in Q3 2022 year-over-year; TTM through Jun 2023 was $45000.0, a 96.37% decrease, with the full-year FY2023 number at $81000.0, down 92.14% from a year prior.
  • Revenue was $45000.0 for Q3 2022 at Actinium Pharmaceuticals, roughly flat from $45000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $940000.0 in Q1 2022 to a low of $23000.0 in Q4 2021.